Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.64 |
| ▸ | VCP | P55072 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5211632 | 0.99 | HRH3 (0.63) | HRH3VCPKDM4ETP53CHRNA10 | |
| SCHEMBL6132583 | 0.82 | HRH3 (0.50) | HRH3KDM4ETP53CHRNA10CHRNA9 | |
| SCHEMBL23384006 | 0.82 | KDM4E (0.61) | HRH3KDM4ETP53CHRNA10CHRNA9 | |
| SCHEMBL5212466 | 0.81 | HRH3 (0.48) | HRH3 | |
| SCHEMBL5212226 | 0.81 | HRH3 (0.54) | HRH3PANK3 | |
| Hydrochloric Acid SCHEMBL5208875 | 0.80 | KDM4E (0.47) | HRH3KDM4ETP53CHRNA10CHRNA9 | |
| Hydrochloric Acid SCHEMBL5211669 | 0.80 | HRH3 (0.47) | HRH3 | |
| Hydrochloric Acid SCHEMBL5214485 | 0.80 | HRH3 (0.53) | HRH3PANK3 | |
| SCHEMBL20346944 | 0.79 | KDM4E (0.53) | HRH3KDM4ETP53CHRNA10CHRNA9 | |
| SCHEMBL4233978 | 0.78 | HRH3 (1.00) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080380-A1 | Therapeutic Uses | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-03-19 | — | — | US | claimed |
| EP-2804853-A1 | THERAPEUTIC USES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-11-26 | — | — | EP | claimed |
| WO-2013107336-A1 | THERAPEUTIC USES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-07-25 | — | — | WO | claimed |
| EP-1646620-B1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | claimed |
| US-20150080380-A1 | Therapeutic Uses | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| US-20150080380-A1 | Therapeutic Uses | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| EP-2804853-A1 | THERAPEUTIC USES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013107336-A1 | THERAPEUTIC USES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013107336-A1 | THERAPEUTIC USES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-07-25 | — | — | WO | disclosed |
| EP-1646620-B1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080380-A1 | Therapeutic Uses | HRH3, HRH4, HRH2 | HRH3 1/4885VCP 3764/4885KDM4E 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.